Transitioning from clozapine to Cobenfy (xanomeline-trospium chloride) in treatment resistant schizophrenia and clozapine induced OCD
Abstract Background Treatment-resistant schizophrenia (TRS) is defined as nonresponse to at least two adequate antipsychotic trials at therapeutic doses for six or more weeks. Currently, clozapine is the only antipsychotic approved for TRS by the FDA and a plethora of evidence indicates that it is t...
Збережено в:
| Автори: | , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMC
2026-05-01
|
| Серія: | BMC Psychiatry |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1186/s12888-026-07795-7 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|